239 related articles for article (PubMed ID: 21396836)
1. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder.
Wang H; Albadine R; Magheli A; Guzzo TJ; Ball MW; Hinz S; Schoenberg MP; Netto GJ; Gonzalgo ML
Urol Oncol; 2012; 30(4):428-33. PubMed ID: 21396836
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer.
Warrick JI; Raman JD; Kaag M; Bruggeman T; Cates J; Clark P; DeGraff DJ
Urol Oncol; 2016 Jun; 34(6):258.e1-6. PubMed ID: 26976725
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of EZH2 indicates aggressive potential of urothelial carcinoma of the bladder in a Chinese population.
Zhou X; Liu N; Zhang J; Ji H; Liu Y; Yang J; Chen Z
Sci Rep; 2018 Dec; 8(1):17792. PubMed ID: 30542123
[TBL] [Abstract][Full Text] [Related]
4. Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection.
Luo Q; Liu Y; Zhao H; Guo P; Wang Q; Li W; Li G; Wu B
World J Urol; 2020 Nov; 38(11):2849-2856. PubMed ID: 31965287
[TBL] [Abstract][Full Text] [Related]
5. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
[TBL] [Abstract][Full Text] [Related]
6. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
Rink M; Park K; Volkmer BG; Xylinas E; Hansen J; Cha EK; Robinson BD; Hautmann R; Küfer R; Engel O; Chun FK; Dahlem R; Rubin MA; Shariat SF; Mosquera JM
Urol Oncol; 2013 Nov; 31(8):1716-24. PubMed ID: 22944196
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
9. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
10. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
[TBL] [Abstract][Full Text] [Related]
11. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.
Fairey AS; Daneshmand S; Wang L; Schuckman A; Lieskovsky G; Djaladat H; Cai J; Miranda G; Skinner EC
Urol Oncol; 2014 Feb; 32(2):110-6. PubMed ID: 23499168
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
Guo YS; Dai YP; Li W; Liu LD
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.
Li Q; Assel M; Benfante NE; Pietzak EJ; Herr HW; Donat M; Cha EK; Donahue TF; Bochner BH; Dalbagni G
Eur Urol Focus; 2019 Jan; 5(1):104-108. PubMed ID: 28753857
[TBL] [Abstract][Full Text] [Related]
14. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
Alford SH; Toy K; Merajver SD; Kleer CG
Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
17. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
[TBL] [Abstract][Full Text] [Related]
18. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
20. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
[No Abstract] [Full Text] [Related]
[Next] [New Search]